“…Recently, it has been reported that ACC1 is overexpressed in human cancer cells, such as colon, prostate, kidney, spleen, uterine cervix, uterus body, ovary, and small intestine cancer cells and is likely involved in tumor development and progression. Thus, ACC1 is a potential target for developing novel agents as cancer therapeutics. − However, selective ACC1 inhibitors have not been reported even though there are many reports for dual ACC1/2 inhibitors − and selective ACC2 inhibitors. − For evaluation of its potential in cancer therapy, a selective ACC1 inhibitor is required. Therefore, we initiated an investigation into the generation of potent and selective ACC1 inhibitors.…”